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In 28 adult patients with atopic dermatitis participat-
ing in a double-blind controlled clinical trial for systemic 
treatment with a new chromone compound, immune 
monitoring were performed with a number of in vitro 
tests. The parameters were phytohemagglutinin, poke-
weed mitogen, concanavalin A, purified protein tuber-
culin derivative, Escherichia coli, Staphylococcus au reus, 
streptokinase/streptodornase, and allogene lympho-
cytes in a one-way mixed lymphocyte culture. No benefit 
could be proven for the drug in the clinical investigation 
or any change in the immunological ' tests during the 
trial. There was no demonstrable differences in the ap-
plied immunoparameters between mild and severe 
atopic dermatitis. The study group was compared with 
an age- and sex-matched control g-roup and a general 
tendency to decreased T-cell function in the PHA, PWM, 
PPD and MLC tests together with a slightly increased 
HEAC percentage was found in the patients with atopic 
dermatitis. 
Immunological mechanisms have been investigated inten-
sively in atopic dermatitis and lately reviewed by Maize [1], 
Hanifin and Lobitz [2] and Strannegard and Strannegard [3]. 
One hypothesis assumes a genetically determined increased 
sensitivity of lymphocytes to cAMP causing a decreased T-cell 
function and a decreased suppressor activity of the IgE group 
ofB-lymphocytes resulting in an increased IgE production. The 
impau'ed T-cell response is in agreement with clinical observa-
tions that patients with atopic dermatitis are disposed to infec-
tions with certain viruses and dermatophytes, and are less liable 
to respond to tuberculin and dinitrochlorobenzene. 
The aim of this investigation was to monitor lymphocyte 
function in a defined population of patients dUJ'ing a clinical 
trial with a new chromone compound, which we were the first 
to investigate in atopic dermatitis, and compare this study 
group to an age- and sex-matched control group. The chromone, 
disodiumcromoglycate (DSCG), has been used topically in 
atopic dermatitis with good result in one investigation [4], but 
without benefit in another [5]. This new oral anti-allergic drug 
(chromone-2-carbocylic acid, C 17 H IS Or" code name FPL 57787) 
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PWM: pokeweed mitogen 
SRBC: unsensibilized sheep erytlu-ocytes 
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was manufactured by Fison Limited, England and has shown 
promising properties in in vitro investigation and in the sys-
temic treatment of asthma (Fison Limited, Pharmaceutical 
Dificion, unpublished data) . 
MATERIALS AND METHODS 
The investigation deals with 28 patients, 13 men and 15 women, with 
atopic dermatitis, who fulfilled the criteria of Hanifin and Lobitz [2]. 
The mean age was 29.1 yr ± 8.2 SD and range was between 19-48 yr. 
One patient did not fulfill t he entire trial and is only included concerning 
the prut of the analysis in which he participated. 
On admission each patient was allocated at random to one of the 
two treatment groups. One group (14 patients) received tablets of 6 mg 
FPL 57787 4 times a day for 6 weeks and the other group was given 
placebo. All patients received placebo for 2 weeks before and 2 weeks 
after this period. Previous treatment was stopped. The patients were 
seen once a week and each time were given 50 gm hydrocortisone 
butyrate 0.1 % in cream (Locoid, Gist-Brocades) and asked to use topical 
treatment only to relieve discomfort. 
Blood tests for immunological investigation were taken at the end of 
week 2 of the trial (in the ftrst placebo-period) , at the end of week 7 (in 
the active/ placebo period) and at the end of week 12 (2 weeks after the 
last placebo-period) . 
The following criteria were used to evaluate the patients: 
1. The number of regions involved in the disease at the first visit: 
The body was divided into 14 regions (scalp, face, neck, shoulders, 
upper trunk, lower trunk, genito-anal region, axillae, cubital fossae, 
wrists, hands, popliteal fossae, ankles and feet). 
2. Total serum IgE at the first visit. 
3. Disease activity at the first visit was estimated on an arbitrru'y 
scale from 1 to 3 (1 = none; 2 = slight and 3 = marked) for color, 
scaling, inftltration and itching of the 3 most active eczematous regions. 
Maximal obtainable sum of points was 36 (see Table I) . 
4. Change in the disease activity during the observation period was 
expressed as t he ratio of disease activity of the 3 most active eczematous 
regions at the fU'st visit divided by disease activity of the same regions 
at the last visit. If the patient improved during the trial the proportion 
would be < 1.00 and > 1.00, if the patient got worse. 
Immunological Investigations 
The immunological tests were compared in the following groups: 
r. Patients with atopic dermatitis divided in a treatment and a 
placebo group. 
II. Patients with atopic dermatitis evaluated according to quantit.a-
tive clinical variables and divided into 2 groups above and below the 
median. 
III. Patients with atopic dermatitis compared with an age- and sex-
matched group of normal persons. 
The control group is part of a larger material composed of 300 
persons in a range from 5 to 100 years divided into 5-)'I'groups with 8 
persons of each sex. As the age limit of the patient material with ± 1 
SD was 20.9-37.3 years, consequently, an age group from 20 to 40 yr of 
nOJ:mal persons were chosen for comparison. This group included 32 
men and 32 women. The normal material was tested 3 times on different 
occasions [7]. Those tests were performed concurrently with this study. 
Blood Samples 
Samples of peripheral venous blood were taken using heparin as an 
anticoagulrult . The blood samples were separated by gravity-gradient 
centrifugation and the lymphocyte suspensions obtained were frozen 
using a cryobiological freezing technique. The freezing technique has 
been described earlier in detail [8, 9]. 
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TABLE 1. Correlation of the number of 14 possibly affected regions 
to disease activity and serum IgE at the first visit in 27 p atients with 
atopic dermatitis 
Disease activity 
No. of re- No. of of the 3 most Total 19E units/ml b<ions af- patients active regions fected (max. (27) (max. 36 points) 14} 
x Range x Range 
1- 2 2 22 17- 26 775 670- 880 
3-4 8 20 15-26 788 6- 2,200 
5-6 4 21 16-24 2,602 68- 8,600 
7-8 5 23 16-33 2,746 140- 6,350 
9-10 8 22 13-29 2,820 1- 10,000 
Rosette Tests 
Heparinized blood was mixed with medium TC 199 containing 
HEPES buffer (Flow) , heparin, and penicillin-streptomycin. Iron car-
bonyl powder was added and phagocytosing cells removed with a 
magnet. Lymphocytes were isolated using Ficoll-Isopaque and were 
washed twice with medium T C 199 containing the additives described 
above, plus 20% human AB serum screened for leukocyte antibodies. 
The lymphocyte suspensions were adjusted to contain 3 X IOu lympho-
cytes per mi. 
BEAC Rosettes (B lymphocytes) 
A system with human type A erythrocytes, rabbit anti-A and mouse 
complement was used. The erythrocytes were diluted with Hanks' 
balanced salt solution and incubated with rabbit anti-A and subse-
quently with mouse complement. Rosettes were formed by incubating 
the lymphocyte suspension with the sensibilized erythrocyte suspension 
for. 5 min at room temperature. The number of rosettes formed by 200 
lymphocytes was counted in a counting chamber. 
E rosettes (T lymphocytes) 
Unsensibilized sheep erythrocytes (SRBC) in H anks ' balanced salt 
solut ion were incubated with a lymphocyte suspension and human AB 
serum pre-absorbed with SRBC for 18 hr at 4°C. The numbers of 
rosettes formed by 200 lymphocytes were counted in a counting cham-
ber. Rosettes with 3 or more, 2 and 1 erythrocyte were counted 
separately: Further details of t he rosettes technique can be found in an 
earlier publication [11]. 
Lymphocyte Transformation Tests 
0.5 mI cultures conta ining 2 x 10" responder cells (Coulter Counter) 
were used. The cultures were stimulated with phytohemagglutinin 
(PHA) (Difco; 6.25 Jlg/vial), pokeweed mitogen (PWM) (Difco; 250 Jlg/ 
vial) , tuberculin purified protein derivative (PPD) (S tatens Serum 
Institute, Copenhagen; 50,000 i.u./mI; 0.2 Jlg/vial) and allogene cells in 
one-way mixed lymphocyte culture (MLC), with the stimulating cells 
treated with 2000 rad from a 137CS source (total of 4 x 10" cells per 
vial). After incuba tion for 7 days and "c thymidine incorporation for 
20 hr, the cultures were harvested with a multiple cell culture harvester 
(Skatron). The results of scintilla tion counting were expressed as dis-
integrations per minute (dpm) . Cultures were made in triplicate. The 
results were given as t he mean ± -1 SD. Details of the culture technique 
have been described earlier [8, 9]. MLC tests were carried out using.the 
individual patients' lymphocytes as responder cells, but using an MLC 
of t he type R + P" where P, is a pool of 3 different lymphocyte 
suspensions (A, + B, + C, ) with different tissue types. The same p, 
was used in all cases. 
S tatistics 
The rosette tests were done in duplicate. The lymphocyte cultures 
were done in triplicate. The average was calculated as mean ± 1 SD. 
Comparison within a group has been carried out with Wilcoxon's test 
for pair differences, and comparison between 2 groups has been carried 
out with Mann-Whitney's rank sum test. 
RESULTS 
I. Effect of Treatment with Chromone Compound 
The clinical trial showed no effect of the tested chromone 
compound [6]. The above mentioned immunoparameters of the 
treatment group and of the placebo group were compared. No 
Vol. 76, No.5 
changes were observed. Within the placebo group no significant 
changes were seen dW'ing the trial. In the treatment group, 
however, the response to PPD was decreased between the 2nd 
and the 3rd specimen (p < 0.04). 
II. Investigation of Disease Activity and Course in the Group 
of Patients with Atopic Dermatitis 
In this part of the investigation the 27 patients were ranged 
according to clinical parameters as described in the method 
section. Severe and mild atopic dermatitis was defined by 
dividing the patients in 2 groups of equal size above and below 
the median value. The following clinical parameters were in-
vestigated: numbers of regions involved at the fIrst visit, total 
serum IgE at the fIrst visit, disease activity at the first visit and 
reduction in disease activity during the trial (Table II) . No 
significant changes were found between the severe and mild 
atopic dermatitis. The results ofthe potentially most.interesting 
comparison: Serum IgE in relation to T and B cells shows 
nonsignificant differences in the figures in the severe and mild 
atopic dermatitis for T cells (73.6 ± 4.7, 71.7 ± 4.1 respectively) 
and B cells (20.0 ± 0.8, 20.0 ± 0.7 respectively) . 
III. Comparison of Patients with Atopic Dermatitis and a 
Sex- and Age-matched Control Group 
The results are seen in Table III. A general tendency to lower 
values of the investigated parameters was seen in the group of 
atopic dermatitis. The PHA-test showed a small difference with 
a p-value of 0.06. PWM and PPD gave significantly reduced 
responses in the transformation tests (p < 0.001 and p < 
0.0001). No changes were seen with stimulation with concana-
TABLE II . Disease activity and course in 27 patients with atopic 
dermatitis 
No. of regions involved at 
the first visit (max. 14) 
Total serum IgE at the 
first visit (units/ mI) 
Disease activity at the 
first visit (max. 36 
points) 
Change in disease activ-
ity during the trial 
Severe atopic dermatitis 
Mean Range 
8.4 5-10 
4773 1350-10000 
26 23-33 
0.73 1.21-0.38 
Mild atopic derma-
titis 
Mean Range 
3.9 2-5 
405 1.2-1300 
17 13-23 
0.22 0.36-0.05 
TABLE III. Patients with atopic dermatitis compared with a control 
group" 
Immune 
Param- Control group Atopic dermatitis Statistics 
etcrs 
PHA 15887 ± 3905 12362 ± 4571 P = 0.06 
PWM 9434 ± 5090 2061 ± 1698 P < 0.0001 
PPD 6872 ± 4484 762 ± 1142 P < 0.001 
Con.A 795 ± 262 715 ± 770 n.S. 
EC 305 ± 218 446 ± 568 n.S. 
SA 450 ± 361 645 ± 783 n.S. 
SK/SD 717 ± 585 570 ± 760 n.S. 
MLC 14434 ± 3543 7513 ± 3371 p < 0.0001 
T·cell 74 .4 ± 2.1 73.0 ± 4.4 n.s. 
B-cell 18.9 ± 0.4 20.1 ± 0.8 p < 0.009 
" The results of the lymphocyte transformation test and the mixed 
lymphocyte culture are given in disintegrations per minute (dpm). 
Nonstimulated controls had dpm < 100. The T-cell and the B-cell are 
expressed as percentages. n.s. means no statistical significance. 
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valin A (Con A), Escherichia coli (EC) and streptokinase/ 
streptodornase (SK/ SD) but in the MLC-test significantly 
lower values for atopic dermatitis appeared (p < 0.0001). The 
percentage of B-Iymphocytes was significantly increased in 
atopic dermatitis (p < 0.009), while the decreased percentage 
of T-Iymphocytes was not statistically significant. 
DISCUSSION 
In this work the patients fulfill commonly accepted criteria 
of atopic dermatitis [2]. We have tried to evaluate the disease 
activity and course according to a proceeding which should be 
reproducible. 
l. The clinical trial of the chromosome derivative showed no 
effect of the drug. This has been confIrmed even with a higher 
dose (11]. Consequently, we neither expected nor found any 
difference between the treatment group and the placebo group 
in respect to immunological tests. The decrease in disease 
activity might be a result of the treatment with hydrocortisone 
butyrate topically and of the fact that the investigation took 
place in the spring and the summer month when most patients 
with atopic dermatitis are getting better. 
II. No differences in the immunological tests were shown 
between severe and mild atopic dermatitis judged by the num-
ber of regions at the fIrst visit, total serum IgE at the fIrst visit, 
disease activity at the fIrst visit or reduction in disease activity 
during the trial. 
. :rhe. fIrst is in agreement with some [12-14], and the second 
18 m dIsagreement with others [12, 15, 16]. 
Clinical evaluation of disease activity is subjective and im-
precise and the immunological tests show the result of partly 
unknown, complicated cellular interactions, which make the 
tests sensitive to tiny variations in test performance. These 
fac~ors might explain the poor correlation, even in this investi-
gation where day-to-day culture variations were eliminated 
because the specimens were analyzed in one seance. This was 
possible due to the used freezing and storage technique for 
lymphocytes. Whether this technique changes subpopulations 
of lymphocytes in patients with atopic dermatitis can be dis-
cussed but has not been shown in other immune diseases where 
this technique has been applied. 
The decrease in disease activity during the observation period 
could not be correlated to changes in the immunological tests. 
Lobitz, Honeyman, and Winkler [18] showed in a patient with 
severe atopic dermatitis that the PHA response normalized 
during a remission of 4 mo duration. Hovmark [14] was not able 
to show ch~n~es in T-cell percentage or PPD or PHA response 
durmg reml8SlOns of more than 2 mo duration. So, longitudinal 
studies during remission or a permanent cure must be of more 
than two months' duration to show changes ' in the T-cell 
percentage or in the lymphocyte transformation tests. 
III. The comparative investigation between patients with 
atopic dermatitis and an age- and sex-matched control group 
showed a general tendency to depressed T-cell function. 
Numerous investigations concerning T-cell function in pa-
tients with atopic dermatitis generally have shown decreased 
T-cell activity [1-3]. 
Meanwhile there have been many disagreements which can 
be due partly to variations in methods of the tests, partly to 
variations in the evaluation of the patients. 
Normal T-cell percentage has been found by some [12, 18, 
19, 21], but more often the percentage has been decreased [13, 
14, 16, 20, 22, 23]. It has been claimed [3] that most of the 
aut~ors reporting equal T-cell values in atopic and nonatopic 
subjects have been using an E-rosette technique giving a normal 
value of about 45% for relative numbers of T -cells. Such meth-
ods would, therefore, be presumed to preferentially detect a 
subpopulation of T -cells with a high avidity for sheep erythro-
cytes. However, in this work the normal percentage of T-cells 
was high, 73.0 ± 4.4%. As shown by Byrom and Timlin [24] 
fetal calf serum might induce normal T-cell values in patients 
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with atopic dermatitis, but fetal calf serum was not used in the 
present investigation. 
The higher B-Iymphocyte percentage is in agreement with 
some [13, 14, 19, 20], but not others [16, 18, 21, 23] while 
~achelefsky et al [13] found n.ormal B-cell percentage, but an 
mcreas~~ total number. The ~Igher B-cell percentage in atopic 
dermatitis may be due to an mcreased number of IgE-bearing 
lymphocytes [21, 25]. 
The normal PHA response is in agreement with many authors 
[14, 16, 18, 22], but not others [15, 23]. The PWM response was 
signifIcantly reduced in atopic dermatitis as found previously 
[13], but not by Thestrup-Pedersen et al [16]. The reduction in 
the PPD lymphocyte transformation was pronounced in this 
investigation as well as in Hovmark's [14]. 
Con A gave a normal stimulation in this investigation. The-
strup-Pedersen et al [16] found reduced response of Con A with 
autologous serum in the test system but a normal response 
without it. 
Bacterial antigens EC, Staphylococcus aureus (SA), and SKI 
SD gave the same stimulation of lymphocytes in the patients 
and in the controls. As far as we know, these antigens have not 
been used in these in vitro tests before. 
The MLC response was significantly reduced. This antigen 
system has not to our knowledge been used previously, although 
it is known to be a good system for screening T-cell function. 
Three major immunological responses are depressed in the 
atopic dermatitis patients described in this study versus con-
trols: The mixed lymphocyte reaction and pokeweed mitogen 
and PPD lymphocyte mitogenesis. Each of these responses 
involve an interplay of helper and suppressor cells. lmmuno-
regulation in atopic dermatitis is thought to be important in 
the complex immunologic aberrations found in these patients. 
The most likely theory at present concerning the immune 
pathogenesis seems to be that these patients have a decreased 
number of a subgroup ofT-cells acting as suppressors of certain 
B-Iymphocytes, probably those producing IgE. How these 
changes in the immune suppressor capacity lead to the different 
signs and symptoms in atopic dermatitis is still unclear. Future 
research concerning the immune pathogenesis of atopic der-
matitis ought to include analysis oflymphocyte subpopulations 
especially in the helper and suppressor groups. Such assessment 
may help in developing in vitro tests of immune function that 
can be used evaluate the effects of treatment. 
This work was supported by the Danish Medical Research Council, 
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Stanford University's Department of Dermatology is presenting the Third International Psoriasis 
Symposium, to be held July 13- 17, 1981, at Stanford University. Significant advances in psoriasis research 
and therapy will be emphasized through plenary sessions, workshops, and poster exhibits, during which 
opportunities for direct discussions between investigators and attendees will be provided. This seminar is 
accredited by AMA, CMA, and AAD. For further information please contact: Paul H. Jacobs, M.D. , 
Dermatology Department, Stanford University School of Medicine, Stanford, CA 94305. 
